From Nasdaq:

Vera Therapeutics (NASDAQ: VERA) had a successful week on the stock market, with share prices rising by 22% over five trading days. The company appointed a new chief medical officer and chief development officer on Monday. Analyst Pete Stavropoulos initiated coverage of the stock with a buy recommendation, citing the company’s investigational treatment Atacicept for autoimmune disorders. However, The Motley Fool Stock Advisor analyst team did not include Vera Therapeutics in their 10 best stocks for investors to buy now. Amgen is recommended by The Motley Fool.



Read more: Why Vera Therapeutics Stock Soared by 22% This Week